Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research
Valentina Franco, Meir Bialer, Emilio Perucca
Neuropharmacology (2021) Vol. 185, pp. 108442-108442
Closed Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic
Lucile Rapin, Rihab Gamaoun, Cynthia El Hage, et al.
Journal of Cannabis Research (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 66
The pharmacological treatment of epilepsy: recent advances and future perspectives
Emilio Perucca
Acta Epileptologica (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 62
Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies
Doodipala Samba Reddy
Experimental Neurology (2022) Vol. 359, pp. 114237-114237
Open Access | Times Cited: 50
Cannabis, Cannabinoids and Cannabis-Based Medicines in Cancer Care
Donald I. Abrams
Integrative Cancer Therapies (2022) Vol. 21
Open Access | Times Cited: 39
A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management
Shampa Ghosh, Jitendra Kumar Sinha, Soumya K. Ghosh, et al.
Brain Sciences (2023) Vol. 13, Iss. 9, pp. 1305-1305
Open Access | Times Cited: 34
Fundamental Neurochemistry Review: GABAA receptor neurotransmission and epilepsy: Principles, disease mechanisms and pharmacotherapy
Alexander Bryson, Christopher A. Reid, Steven Petrou
Journal of Neurochemistry (2023) Vol. 165, Iss. 1, pp. 6-28
Open Access | Times Cited: 22
Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?
Leontina Elena Filipiuc, Daniela Carmen Ababei, Teodora Alexa‐Stratulat, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1823-1823
Open Access | Times Cited: 54
Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders
Muhammad Yousaf, Dennis Chang, Yang Liu, et al.
Molecules (2022) Vol. 27, Iss. 15, pp. 4961-4961
Open Access | Times Cited: 34
The Contribution of HCN Channelopathies in Different Epileptic Syndromes, Mechanisms, Modulators, and Potential Treatment Targets: A Systematic Review
Miriam Kessi, Jing Peng, Haolin Duan, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 29
Therapeutic Approach to Epilepsy in Patients with Mitochondrial Diseases
Jihoon Na, Young‐Mock Lee
Yonsei Medical Journal (2025) Vol. 66
Open Access
From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications
Meir Bialer, Emilio Perucca
Pharmacology & Therapeutics (2025), pp. 108808-108808
Open Access
Pharmacokinetic variability and use of therapeutic drug monitoring of cannabidiol in patients with refractory epilepsy
Cecilie Johannessen Landmark, Johan Sætre, André Gottås, et al.
Epilepsia (2025)
Closed Access
Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs
Gabriel Garcia, Stephanie Kube, Sheila Carrera‐Justiz, et al.
Frontiers in Veterinary Science (2022) Vol. 9
Open Access | Times Cited: 20
Discriminating different Cannabis sativa L. chemotypes using attenuated total reflectance - infrared (ATR-FTIR) spectroscopy: A proof of concept
Marco Cirrincione, Bruno Saladini, Virginia Brighenti, et al.
Journal of Pharmaceutical and Biomedical Analysis (2021) Vol. 204, pp. 114270-114270
Closed Access | Times Cited: 25
Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis
Melissa Barker‐Haliski, Nicole A. Hawkins
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1099-1113
Closed Access | Times Cited: 3
Seizures and Epilepsy in Childhood
Μαρία Γώγου, J. Helen Cross
CONTINUUM Lifelong Learning in Neurology (2022) Vol. 28, Iss. 2, pp. 428-456
Closed Access | Times Cited: 15
Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome
Cristina Alonso, Valentina Satta, Inés Hernández-Fisac, et al.
Neuropharmacology (2023) Vol. 237, pp. 109602-109602
Open Access | Times Cited: 8
Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments
Hugo Bayer, Cristina Aparecida Jark Stern, Fernanda Troyner, et al.
Neuropharmacology (2021) Vol. 205, pp. 108913-108913
Closed Access | Times Cited: 18
Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery
Aarón del Pozo, Melissa Barker‐Haliski
Experimental Neurology (2022) Vol. 360, pp. 114288-114288
Open Access | Times Cited: 13
Cannabidiol mediates epidermal terminal differentiation and redox homeostasis through aryl hydrocarbon receptor (AhR)-dependent signaling
Young Su Jang, Sugyeong Jeong, Aram Kim, et al.
Journal of Dermatological Science (2023) Vol. 109, Iss. 2, pp. 61-70
Closed Access | Times Cited: 7
Restoring prefrontal cortical excitation-inhibition balance with cannabidiol ameliorates neurobehavioral abnormalities in a mouse model of neurodevelopmental disorders
Lu Zhang, Chunqiao Lin, Jiushuang Zhu, et al.
Neuropharmacology (2023) Vol. 240, pp. 109715-109715
Closed Access | Times Cited: 7
Exploring the Antibacterial Potential of Semisynthetic Phytocannabinoid: Tetrahydrocannabidiol (THCBD) as a Potential Antibacterial Agent against Sensitive and Resistant Strains of Staphylococcus aureus
Pankaj Singh Cham, Deepika, Rahul Bhat, et al.
ACS Infectious Diseases (2023) Vol. 10, Iss. 1, pp. 64-78
Closed Access | Times Cited: 7
Cannabinoids for Cancer-related Pain Management: An Update on Therapeutic Applications and Future Perspectives
Sabrina Bimonte, Davide Nocerino, Daniela Schiavo, et al.
Anticancer Research (2024) Vol. 44, Iss. 3, pp. 895-900
Open Access | Times Cited: 2
Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol
Christopher Anderson, Victoria Evans, Laura M. Gorham, et al.
Epilepsy & Behavior (2021) Vol. 124, pp. 108325-108325
Closed Access | Times Cited: 17
Therapeutic Drug Monitoring of Antiseizure Medications Using Volumetric Absorptive Microsampling: Where Are We?
Annachiara D’Urso, Marcello Locatelli, Angela Tartaglia, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 627-627
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top